Filing Details
- Accession Number:
- 0001415889-24-028349
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-04 21:40:04
- Reporting Period:
- 2024-12-02
- Accepted Time:
- 2024-12-04 21:40:04
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1671858 | Ars Pharmaceuticals Inc. | SPRY | Pharmaceutical Preparations (2834) | 811489190 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1951287 | Eric Karas | C/O Ars Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego CA 92130 | Chief Commercial Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-12-02 | 3,717 | $1.50 | 9,410 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-12-02 | 3,717 | $14.11 | 5,693 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-12-04 | 6,283 | $1.50 | 11,976 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-12-04 | 6,283 | $14.00 | 5,693 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-02 | 3,717 | $0.00 | 3,717 | $1.50 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-04 | 6,283 | $0.00 | 6,283 | $1.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
590,871 | 2032-05-23 | No | 4 | M | Direct | |
584,588 | 2032-05-23 | No | 4 | M | Direct |
Footnotes
- The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
- The weighted average sale price for the transaction reported was $14.1139, and the range of prices were between $14.00 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at eachseparate price will be provided.
- Immediately exercisable.